KR960701638A - Stabilized Injections and Stabilization of Injections - Google Patents

Stabilized Injections and Stabilization of Injections

Info

Publication number
KR960701638A
KR960701638A KR1019950704441A KR19950704441A KR960701638A KR 960701638 A KR960701638 A KR 960701638A KR 1019950704441 A KR1019950704441 A KR 1019950704441A KR 19950704441 A KR19950704441 A KR 19950704441A KR 960701638 A KR960701638 A KR 960701638A
Authority
KR
South Korea
Prior art keywords
sulfite
against light
sodium
acid
potassium
Prior art date
Application number
KR1019950704441A
Other languages
Korean (ko)
Other versions
KR100188318B1 (en
Inventor
도시유끼 시바따
시게미 기노
도시오 하마사끼
다께시 가와끼따
Original Assignee
고오야 마사시
요시또미 세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고오야 마사시, 요시또미 세이야꾸 가부시끼가이샤 filed Critical 고오야 마사시
Publication of KR960701638A publication Critical patent/KR960701638A/en
Application granted granted Critical
Publication of KR100188318B1 publication Critical patent/KR100188318B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

본 발명은 빛에 대한 안정화제를 배합하는 것을 특징으로 하는 (±)-6-클로로-3,4-디히드로-4-메틸-3-옥소-N-3-퀴누클리디닐-2H-1,4-벤족사진-8-카르복스아미드 일염산염을 유효성분으로 하는 안정화된 주사제 및 안정화 방법에 관한 것이다.(±) -6-chloro-3,4-dihydro-4-methyl-3-oxo-N-3-quinuclidinyl-2H-1, characterized in that the present invention is formulated with a stabilizer against light. A stabilized injectable agent and a stabilizing method comprising 4-benzoxazine-8-carboxamide monohydrochloride as an active ingredient.

아황산, 아황산염, 아스코르빈산, L-시스테인 또는 그의 산부가염, 티오글리콜산 또는 그의 금속염, 에틸렌디아민, 살리실산 또는 그 금속염, 또는 페놀 또는 그의 유도체로 부터 선택된 1종 또는 2종 이상의 빛에 대한 안정화제를 배합하는 것에 의해 착색 방지가 나타난다.One or two or more light stabilizers selected from sulfites, sulfites, ascorbic acids, L-cysteine or acid addition salts thereof, thioglycolic acid or metal salts thereof, ethylenediamine, salicylic acid or metal salts thereof, or phenols or derivatives thereof Coloring prevention appears by compounding.

Description

안정화된 주사제 및 주사제의 안정화법Stabilized Injections and Stabilization of Injections

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (10)

빛에 대한 안정화제를 배합하는 것을 특징으로 하는 (±)-6-클로로-3,4-디히드로-4-메틸-3-옥소-N-3-퀴누클리디닐-2H-1,4-벤족사진-8-카르복스아미드 일염산염을 유효 성분으로 하는 안정화된 주사제.(±) -6-chloro-3,4-dihydro-4-methyl-3-oxo-N-3-quinuclidinyl-2H-1,4-benzone characterized by combining a stabilizer against light Photo-8-Carboxamide monohydrochloride stabilized injectable drug as an active ingredient. 제1항에 있어서, 빛에 대한 안정화제가 아황산, 아황산염, 아스코르빈산, L-시스테인 또는 그의 산부가염, 티오글리콜산 또는 그의 금속염, 에틸렌디아민, 살리실산 또는 그 금속염, 또는 페놀 또는 그의 유도체로부터 선택된 1종 또는 2종 이상인 주사제.The stabilizer for light according to claim 1, wherein the stabilizer against light is selected from sulfurous acid, sulfite, ascorbic acid, L-cysteine or acid addition salts thereof, thioglycolic acid or metal salts thereof, ethylenediamine, salicylic acid or metal salts thereof, or phenol or derivatives thereof. Species or two or more injections. 제1항 또는 제2항에 있어서, 빛에 대한 안정화제가 아황산염으로 부터 선택된 1종 또는 2종 이상인 주사제.The injection according to claim 1 or 2, wherein the stabilizer against light is one or two or more selected from sulfites. 제1항, 제2항 또는 제3항에 있어서, 아황산염이 아황산 나트륨, 아황산 칼륨, 아황산 수소나트륨, 아황산수소칼륨, 피로아황산 나트륨, 피로아황산 칼륨으로 부터 선택된 주사제.The injection according to claim 1, 2 or 3, wherein the sulfite is selected from sodium sulfite, potassium sulfite, sodium hydrogen sulfite, potassium hydrogen sulfite, sodium pyrosulfite, potassium pyrosulfite. 유효성분으로서 (±)-6-클로로-3,4-디히드로-4-메틸-3-옥소-N-3-퀴누클리디닐-2H-1,4-벤족사진-8-카르복스아미드 일염산염을, 빛에 대한 안정화제로서 피로아황산 나트륨을 포함하는 것을 특징로 하는 안정화된 주사제.(±) -6-chloro-3,4-dihydro-4-methyl-3-oxo-N-3-quinuclidinyl-2H-1,4-benzoxazine-8-carboxamide monohydrochloride as an active ingredient A stabilized injectable agent comprising sodium pyrosulfite as a stabilizer against light. 유효성분으로서 (±)-6-클로로-3,4-디히드로-4-메틸-3-옥소-N-3-퀴누클리디닐-2H-1,4-벤족사진-8-카르복스아미드 일염산염을 함유하는 주사제에 빛에 대한 안정화제를 배합하는 젓을 특징으로 하는 주사제의 안정화 방법.(±) -6-chloro-3,4-dihydro-4-methyl-3-oxo-N-3-quinuclidinyl-2H-1,4-benzoxazine-8-carboxamide monohydrochloride as an active ingredient A method of stabilizing an injectable agent, comprising mixing a stabilizer against light with an injection containing the compound. 제6항에 있어서, 빛에 대한 안정화제가 아황산, 아황산염, 아스코르빈산염, L-시스테인 또는 그의 산부가염, 티오글리콜산 또는 그의 금속염, 에틸렌 디아민, 살리실산 또는 그의 금속염, 또는 페놀 또는 그의 유도체로 부터 선택된 1종 또는 2종 이상인 안정화 방법.7. The stabilizer for light according to claim 6, wherein the stabilizer against light is from sulfite, sulfite, ascorbate, L-cysteine or acid addition salts thereof, thioglycolic acid or metal salts thereof, ethylene diamine, salicylic acid or metal salts thereof, or phenol or derivatives thereof. Stabilization method is one or two or more selected. 제7항에 있어서, 빛에 대한 안정화제가 아황산염으로 부터 선택된 1종 또는 2종 이상인 안정화 방법.The stabilizing method according to claim 7, wherein the stabilizing agent for light is one or two or more selected from sulfites. 제6항, 제7항 또는 제8항에 있어서, 아황산염이 아황산 나트륨, 아황산 칼륨, 아황산 수소 나트륨, 아황산 수소 칼륨, 피로아황산 나트륨, 피로아황산 칼륨으로 부터 선택된 안정화 방법.9. The method of claim 6, 7, or 8, wherein the sulfite is selected from sodium sulfite, potassium sulfite, sodium hydrogen sulfite, potassium hydrogen sulfite, sodium pyrosulfite, potassium pyrosulfite. 빛에 대한 안정화제로서 피로아황산 나트륨을 배합하는 것을 특징으로 하는 (±)-6-클로로-3,4-디히드로-4-메틸-3-옥소-N-3-퀴누클리디닐-2H-1,4-벤족사진-8-카르복스아미드 일염산염을 함유 주사제의 안정화 방법.(±) -6-chloro-3,4-dihydro-4-methyl-3-oxo-N-3-quinucridinyl-2H-1 characterized by incorporating sodium pyrosulfite as a stabilizer against light A method for stabilizing injections containing, 4-benzoxazine-8-carboxamide monohydrochloride. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019950704441A 1993-04-28 1994-04-25 Stabilized injection and method of stabilizing injection KR100188318B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP12497893 1993-04-28
JP93-124978 1993-04-28
PCT/JP1994/000691 WO1994025032A1 (en) 1993-04-28 1994-04-25 Stabilized injection and method of stabilizing injection

Publications (2)

Publication Number Publication Date
KR960701638A true KR960701638A (en) 1996-03-28
KR100188318B1 KR100188318B1 (en) 1999-06-01

Family

ID=14898921

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950704441A KR100188318B1 (en) 1993-04-28 1994-04-25 Stabilized injection and method of stabilizing injection

Country Status (3)

Country Link
KR (1) KR100188318B1 (en)
CN (1) CN1047076C (en)
WO (1) WO1994025032A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6369796A (en) * 1995-08-04 1997-03-05 Hokuriku Seiyaku Co. Ltd Photostable aqueous solution containing benzyl alcohol derivatives
JP2008297277A (en) * 2007-06-01 2008-12-11 Taiyo Yakuhin Kogyo Kk Method for stabilizing parenteral injection
EP2343078A4 (en) * 2008-09-30 2012-05-16 Denki Kagaku Kogyo Kk Light-stabilized pharmaceutical composition
CN103432078B (en) * 2013-08-28 2015-06-17 芦红代 Medicinal composition of cefmenoxime hydrochloride
WO2018021518A1 (en) * 2016-07-29 2018-02-01 東レ株式会社 Solid preparation having improved light stability
CN106943310B (en) * 2017-01-25 2020-07-17 西安科艺诗生物技术有限公司 Compound for improving light stability of chromoprotein and application
CN116158429A (en) * 2021-11-25 2023-05-26 沈阳中化农药化工研发有限公司 Stable liquid preparation containing biphenyl compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3597456A (en) * 1969-05-20 1971-08-03 Squibb & Sons Inc Method for preparing sterile lecithin
JPS4819929B1 (en) * 1970-05-12 1973-06-18
JPS51136818A (en) * 1975-05-20 1976-11-26 Yamanouchi Pharmaceut Co Ltd Method for preparing stable prostaglandine pharma ceuticals
JPS5270014A (en) * 1975-12-05 1977-06-10 Senju Pharma Co Stabilization of pyrido*3*22a*phenoxadine compounds
JPS58203910A (en) * 1982-05-20 1983-11-28 Nikken Kagaku Kk Agent for intravenous drip containing dapamine
JPS60169430A (en) * 1984-02-14 1985-09-02 Teijin Ltd Composition for prostaglandin preparation
JPH0778020B2 (en) * 1987-06-10 1995-08-23 日本化薬株式会社 Stable multivitamin freeze-dried preparation
CA1304082C (en) * 1987-10-22 1992-06-23 Tetsuya Tahara Benzoxazine compounds and pharmaceutical use thereof
JP2761005B2 (en) * 1988-11-02 1998-06-04 エーザイ株式会社 Injectable composition containing cephalosporin
NL8901432A (en) * 1989-06-06 1991-01-02 Pharmachemie Bv STABLE AQUEOUS FOLINATE SOLUTION AT REFRIGERATOR TEMPERATURE, AND METHOD FOR PREPARING THAT.

Also Published As

Publication number Publication date
WO1994025032A1 (en) 1994-11-10
KR100188318B1 (en) 1999-06-01
CN1047076C (en) 1999-12-08
CN1121691A (en) 1996-05-01

Similar Documents

Publication Publication Date Title
ATE121125T1 (en) POURABLE SULFONE-PEROXYCARBONIC ACID COMPOSITION.
ATE245033T1 (en) USE OF METAL ION CHELATORS FOR STABILIZING PHARMACEUTICAL PREPARATIONS CONTAINING INTERFERON
KR950005305A (en) Stable solution of platinum (Ⅱ) antitumor agent
BR9405589A (en) Molding materials and spinning materials containing cellulose
RU94046143A (en) Pharmaceutical composition for glaucoma treatment
KR920019371A (en) Stabilized Factor Ⅷ Formulations
DE58906847D1 (en) Stabilized aqueous solutions of 3-isothiazolinones.
FI944448A0 (en) Stabilized pharmaceutical composition and stabilizing solvent
ES2132676T3 (en) PEROXYGEN COMPOSITIONS.
KR890015745A (en) Pharmaceutical composition of pyricampum present in aqueous solution and preparation method thereof
KR950032201A (en) How to stabilize pranopropene and stable pranopropene liquid
ES2123721T3 (en) RAPAMICINE FORMULATIONS FOR INTRAVENOUS INJECTIONS.
KR910009560A (en) Stabilized Concentrated Hydrogen Peroxide Solution and Its Stabilization Method
KR920002836A (en) Cellulose solution dissolved in water and N-methylmorpholine-N-oxide
KR960701638A (en) Stabilized Injections and Stabilization of Injections
KR970706841A (en) A pharmaceutical composition comprising growth hormone and leucine (A PHARMACEUTICAL FORMULATION COMPRISING A GROWTH HORMONE AND LEUCINE)
KR970706839A (en) A pharmaceutical composition comprising growth hormone and isoleucine (A PHARMACEUTICAL FORMULATION COMPRISING A GROWTH HORMONE AND ISOLEUCINE)
DE69417087T2 (en) Aqueous pharmaceutical preparations containing argatroban and cyclodextrin or caffeine
KR920018015A (en) Stabilization method and stabilized isocyanate composition of isocyanate compound
KR890006238A (en) Stabilized Pergolide Composition
KR950702208A (en) STABLE MOULDING OR SPINNING COMPOUND CONTAINING CELLULOSE
MY107183A (en) Pharmaceutical compositions
KR890001571A (en) Doxorubicin hydrochloride aqueous solution
DE69527686T2 (en) IN LIQUID FORM STABLE THIO ACTIVATOR
KR950005325A (en) Pharmaceutical composition

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
E601 Decision to refuse application
J201 Request for trial against refusal decision
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20121227

Year of fee payment: 15

FPAY Annual fee payment

Payment date: 20131218

Year of fee payment: 16

EXPY Expiration of term